A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
Cancer Lett
; 48(2): 123-4, 1989 Nov 30.
Article
em En
| MEDLINE
| ID: mdl-2555044
ABSTRACT
Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct anti-tumor effect of Zoladex.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Carcinoma Intraductal não Infiltrante
Limite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Cancer Lett
Ano de publicação:
1989
Tipo de documento:
Article
País de afiliação:
Itália